Get started
Work

Efficacy of Combined Rituximab/Daratumumab Therapy in Post-Transplant FSGS Recurrence: A Retrospective, International, Multi-Center Study

Year: 2025
Type: article
Study design: Observational Study
Abstract: Purpose: Focal segmental glomerulosclerosis (FSGS) frequently recurs after kidney transplantation (KT), favoring graft failure. Plasma exchange (PEX) and rituximab show variable effectiveness, and PEX is often poorly tolerated. We previously reported the safety/efficacy of combined anti-CD20 and anti-CD38 (daratumumab) depletion treatments in a few FSGS recurrence cases. Here, we present a multi-center, international, retrospective cohort analysis in early FSGS recurrence following KT treated with combined regimen of rituximab and daratumumab.
DOI: 10.1016/j.ajt.2025.07.2101
Authors: A. Angeletti, P. Cravedi, U. Maggiore, F. Vincenti, F. Alberici, N. Bouvier, G. La Manna, G. Comai, L. Gallon, G. Mortari, E.E. Verrina
Institutions: Istituto Giannina Gaslini, Icahn School of Medicine at Mount Sinai, University of Parma, University of California, San Francisco, University of Brescia, Université de Caen Normandie, University of Bologna, University of Illinois Urbana-Champaign, University of Illinois System
Language: English
Subfield: Transplantation
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,300
OpenAlex ID: W4412851619
FWCI:
Cites:
Cited by:
Related to: 10